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The Progressive MS Alliance
Industry Forum describes a new
approach to address barriers to
developing treatments for progres-
sive multiple sclerosis (MS). This
innovative model promises to facil-
itate robust collaboration between
industry, academia, and patient
organizations and accelerate
research towards the overarching
goal of developing safe and effec-
tive treatments for progressive MS.
Although signiﬁcant progress has been
made in the understanding and treatment
of relapsing-remitting MS, the same can-
not be said for the progressive (primary
and secondary) forms of the disease. Of
the more than 2.3 million people world-
wide living with multiple sclerosis, more
than 1 million live with a progressive form.
These individuals and their care partners
are faced with the challenging reality that
there are still no effective treatments for
progressive MS. Consequently, people
with MS are demanding a renewed focus
on progressive MS and are urging relevant
stakeholders to work together to maxi-
mize their collective impact on developing
new treatments for this devastating form
of the disease.For the ﬁrst time in their collective histories,
the organizations committed to the welfare
ol. 37, No. 10of people living with MS have decided to
work together to promote innovation and
scientiﬁc progress regardless of geo-
graphic boundaries. The initial commit-
ment of MS Societies will be s22 million
over the next 4 years to sustain a long-term
Progressive MS Research Program. The
collaboration, formally known as the Inter-
national Progressive MS Alliance (www.
progressivemsalliance.org/), was estab-
lished in 2012 with the express call to
expedite the development of disease-
modifying and symptoms-management
therapies for people living with progressive
MS. Within this framework, collaboration
with the pharmaceutical and biotechnol-
ogy industry is a crucial element to address
this signiﬁcant challenge.
Patients with Progressive MS
Need Innovative Therapies
In Europe, the burden of brain disorders
was estimated at s798 billion in 2010 and
is growing [1]. The rest of the world faces
similar challenges. The market for dis-
ease-modifying drugs is clearly very large.
However, for chronic degenerative disor-
ders, such as Alzheimer's and Parkinson's
diseases, and for progressive forms of
MS, the process of discovery and valida-
tion of pathogenetic treatments has
almost completely failed, despite decades
of research. After many years of industry
divestment from these areas, some com-
panies are beginning to reinvest, suggest-
ing that neuroscience drug discovery and
development may be poised for a renais-
sance (https://lifescivc.com/2016/02/
are-we-poised-for-a-neuroscience-
research-renaissance-maybe).
Despite these positive developments,
people with progressive MS still lack dis-
ease-modifying treatments [2–4]. The
pharmaceutical sector has concentrated
its efforts and investments on the devel-
opment of anti-inﬂammatory and immuno-
modulatory drugs, and on less-risky
relapsing-remitting MS studies where
the development and regulatory paths
are better deﬁned [5,6]. One key reason
for the lack of advancement is the
absence of a fundamental understanding
of the pathophysiology of disease pro-
gression, and this has prevented signiﬁ-
cant progress that could lead to treatment
[7]. For progressive MS, R&D tools are
unproven or do not exist. With this back-
drop, drug developers must take signiﬁ-
cant risks upfront and perform large
clinical trials, exposing a large number of
patients to treatment without knowing the
probability of being successful.
Pivotal Phase III clinical trials of disease-
modifying agents in progressive MS have
been long, extraordinarily expensive, and
almost always unsuccessful [8]. A recent
study with ocrelizumab in primary pro-
gressive MS found that B cell targeting
had a signiﬁcant effect on conﬁrmed dis-
ease progression, providing some hope
for people with progressive disease, espe-
cially those with active inﬂammation who
are treated early in their disease course [9].
However, anti-inﬂammatory drugs that
target the adaptive immune system, such
as ocrelizumab, likely do not target the
core pathophysiology underlying neuro-
degeneration, and are thus limited in their
potential to affect neurodegeneration
resulting from prior inﬂammatory lesions.
Therefore, people living with progressive
MS need new innovative neuroprotective
and neuroreparative therapies to target
ongoing neurodegenerative processes.
Given the challenges presented, the Alli-
ance recognizes that, for progressive MS
research to be successful and have a more
substantial clinical impact in modifying dis-
ease progression, a new multi-stakeholder
collaborative model is needed.
Progressive MS Alliance Industry
Forum
In 2014 the Progressive MS Alliance estab-
lished the Industry Forum to enable
ongoing collaboration between the phar-
maceutical and biotechnology industry
and the academic and patient organiza-
tions addressing progressive MS. Industry
collaborators are companies, organiza-
tions, and individuals with a shared interestin new and innovative treatments for pro-
gressive MS. The original collaborating
companies include Biogen, EMD Serono,
Genentech, a member of Roche, Novartis
AG, Sanoﬁ Genzyme, and Teva. The active
engagement of pharmaceutical compa-
nies to this call to action illustrated the
shared interest with the academic and
patient communities in ﬁnding solutions
for people living with this devastating form
of the disease.
Governance
In the past decade, stakeholders within
the healthcare ecosystem have launched
collaborative efforts between academia
and industry in an attempt to help neuro-
science deliver innovation and stimulate
new treatment development. However,
many of these initiatives are governed
and driven by industry and academia,
and the relevance of this model has been
recently commented [10]. Historically,
patients and their advocacy organizations
were involved solely as supporters rather
than initiators or partners for translational
initiatives. Today, patient organizations
bring a sense of urgency, focus, and mis-
sion to research that aims to transcend
obstacles to discovery and development
[11].
A key difference of the Progressive MS
Alliance Industry Forum initiative from
most academic/industry partnerships is
that MS patient advocacy organizations
are at the center of the collaboration,
ensuring progress towards the goals of
the Alliance. Oversight is provided by
the Executive Committee of the Alliance,
a body composed of the CEOs of the MS
Societies providing ﬁnancial support for
the Alliance. The scientiﬁc direction of
the Alliance is overseen by its Scientiﬁc
Steering Committee, consisting of scien-
tiﬁc experts and people living with MS from
12 different countries, which reports to the
Executive Committee. The Industry Forum
is an advisory group to the Scientiﬁc
Steering Committee and is composed pri-
marily of R&D representatives from Indus-
try together with representation fromTrends in Pharmpeople with MS, academia, and MS
patient advocacy organizations. The
Industry Forum is co-chaired by one aca-
demic representative of the Scientiﬁc
Steering Committee and one representa-
tive from a collaborating company.
As an advisory group of the Scientiﬁc
Steering Committee, the Industry Forum
serves the essential role of ensuring that
the perspective of those responsible for,
and with expertise in, the development of
new therapies is a constant consideration
throughout the research strategy of the
Alliance. The objective of the Forum is to
remove barriers and create an environment
conducive to open discussions, with the
sole purpose of developing safe and effec-
tive treatments. Further, the governance
structure under the leadership of global
MS advocacy organizations fosters collab-
oration and a patient-centered approach
to drug discovery and development [12].
Strategy: Revitalizing Innovation in
Progressive MS and Creating Networks
of Excellence
Leaders from industry have been engaged
since the outset of the development of the
Alliance's research strategy. In 2012, the
Alliance identiﬁed key priority areas for
research [13]. These areas represent
opportunities where concerted research
efforts could provide signiﬁcant impact
in overcoming the current barriers in
developing effective treatments for pro-
gressive MS (Table 1). In 2014 the Alliance
committed to providing sustainable,
long-term research funding to address
these areas. The launch of the Alliance
research funding initiatives demonstrates
the global commitment by patient orga-
nizations, academia, and industry to
speed solutions in progressive MS.
Furthermore, the leadership of the Indus-
try Forum and Alliance has identiﬁed addi-
tional gaps that must be addressed to
make progress in the development of
innovative treatments and to de-risk drug
discovery and development. These gaps
include standardized drug-discovery toolsacological Sciences, October 2016, Vol. 37, No. 10 809
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hand improved patient selection and strati-
ﬁcation in clinical trials and monitoring dis-
ease progression.
To start addressing these gaps, the Indus-
try Forum has identiﬁed two initial areas of
precompetitive collaboration opportunity:
translational pathophysiology and data
sharing. The successful design of thera-
pies for progressive MS requires signiﬁ-
cant advances in the understanding of the
complex mechanisms underlying disease
progression to identify new targets and
translate research ﬁndings into therapies.
In 2015, a critical appraisal of the transla-
tional potential of current basic scientiﬁc
pathophysiological knowledge was
performed in conjunction with industry
representatives [14]. Precompetitive col-
laboration on translational pathophysiol-
ogy will enable a concerted effort to
prioritize pathogenetic mechanisms and
to standardize relevant drug-discovery
tools.
Data sharing, although raising complex
challenges [15], has been recognized as
a priority by the Industry Forum. A better
understanding of the natural history of
the progressive phase of the disease
with both retrospective and prospective
Table 1. The Progressive MS Alliance: Research
(i) Drug-discovery programs that identify and 
phenotypes, and screen and characterize d
ﬁrst-in-human drugs.
(ii) Design and run smaller, faster trials to enab
outcome measures or biomarkers of progre
therapies for progressive MS.
(iii) Conduct trials to test agents and rehabilitat
measures. With better trial designs, more li
people faster.
(iv) Develop and evaluate new therapies and re
greater access to effective rehabilitation and
quality of life.810 Trends in Pharmacological Sciences, October 2016, Vstudies, bridged with already ongoing
research efforts in the same direction,
is fundamental, as is the creation or con-
solidation of clinical trial datasets and net-
works for the validation of new treatments.
Precompetitive collaboration in this area
will enable the MS community to reﬁne
diagnosis, improve patient selection and
stratiﬁcation in clinical trials, and monitor
disease progression, with the ultimate
goal of improving prediction of efﬁcacy
and safety of innovative treatments for
progressive MS.
Progressive MS Alliance Industry Forum
Challenge
Moving forward to fulﬁll the mission of the
Progressive MS Alliance we should
embrace the unique opportunity to fully
advance the science of multi-stakeholder
collaborations [16]. In this case, collective
impact is a much broader concept than
how research outcomes have traditionally
been measured. Successful outcomes
and metrics will need to be identiﬁed that
reﬂect the shared efforts of the Alliance
and the Industry Forum, and it will be
necessary to develop a relevant infrastruc-
ture to support this work. Establishing
clear goals and a strong foundation will
ensure that all stakeholders remain
 Priorities
alidate molecular and cellular targets and/or
rug candidates, which may be either repurposed or
le clinical proof-of-concept, for example testing new
ssion that could shorten development time for
on treatments using new and existing outcome
-changing treatment choices will be available to
abilitation to manage symptoms. People will have
 symptomatic treatments that improve their dailyol. 37, No. 10engaged and thus enable the collaborative
model of the Industry Forum to be fully
realized and meet the needs of people
living with progressive MS.
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